Sign In
Buy KNSA
$47.85
+0.93 (+1.98%)
At Close: Jun 03, 2026
Bank of New York Mellon Corp Sells 5,989 Shares of Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA)
08:44am, Wednesday, 29'th Apr 2020
Bank of New York Mellon Corp trimmed its stake in shares of Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) by 11.5% in the fourth quarter, according to the company in its most recent Form 13F filing with t
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Upgraded at BidaskClub
06:44am, Wednesday, 29'th Apr 2020
Kiniksa Pharmaceuticals (NASDAQ:KNSA) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, BidAskClub reports. Several other equities a
BRIEF-Kiniksa Reports Q1 2020 Financial Results
11:51am, Tuesday, 28'th Apr 2020
Kiniksa Pharmaceuticals Ltd:
Kiniksa Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity
11:30am, Tuesday, 28'th Apr 2020
– Financial guidance and clinical timelines for rilonacept, mavrilimumab, vixarelimab and KPL-404 remain intact amid COVID-19 pandemic –– Mavrilimumab treatment protocol in.
Kiniksa Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity
11:30am, Tuesday, 28'th Apr 2020
– Financial guidance and clinical timelines for rilonacept, mavrilimumab, vixarelimab and KPL-404 remain intact amid COVID-19 pandemic –– Mavrilimumab...
Sanofi's BTK Progress, And Other News: The Good, Bad And Ugly Of Biopharma
10:58am, Sunday, 26'th Apr 2020
Sanofi's BTK inhibitor shows promise in RRMS. Kiniksa announces positive data from a dermatology trial. Immunomedics receives approval for cancer drug.
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) Stock Position Reduced by Goldman Sachs Group Inc.
08:26am, Sunday, 26'th Apr 2020
Goldman Sachs Group Inc. lessened its position in shares of Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) by 76.9% during the fourth quarter, according to the company in its most recent 13F filing with th
The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt
11:53am, Thursday, 23'rd Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks htitting 52-week highs April 22.) * Dr.Reddy's Laboratories Ltd (NYSE: RDY) * Johns
Zacks: Brokerages Anticipate Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) Will Post Earnings of -$0.62 Per Share
10:04am, Thursday, 23'rd Apr 2020
Analysts expect that Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) will announce ($0.62) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided e
Insider Selling: Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) EVP Sells 47,423 Shares of Stock
10:04am, Thursday, 23'rd Apr 2020
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) EVP Thomas W. Beetham sold 47,423 shares of the business’s stock in a transaction that occurred on Monday, April 20th. The stock was sold at an average pric
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Lifted to "Buy" at Zacks Investment Research
07:34am, Thursday, 23'rd Apr 2020
Kiniksa Pharmaceuticals (NASDAQ:KNSA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday, Zacks.com reports. The brokerage c
Kiniksa's vixarelimab successful in lumpy skin disease
02:36pm, Wednesday, 22'nd Apr 2020
Kiniksa Pharmaceuticals (KNSA +3.0%) announces positive results from a Phase 2a clinical trial evaluating vixarelimab (KPL-716) in 49 patients with moderate-to-severe prurigo nodularis, a disorder ch
CMG, CLDX among premarket gainers
01:19pm, Wednesday, 22'nd Apr 2020
SAExploration Holdings (NASDAQ:SAEX) +177% on $27M new project in Greece.B.O.S. Better Online Solutions (NASDAQ:BOSC) +56% on $1M order.The Peck Company Holdings (NASDAQ:PECK) +51% on partnership w
BRIEF-Kiniksa Announces Phase 2 Clinical Trial Of Vixarelimab Meets Primary Efficacy Endpoint
12:26pm, Wednesday, 22'nd Apr 2020
Kiniksa Pharmaceuticals Ltd:
Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint
12:00pm, Wednesday, 22'nd Apr 2020
- Statistically significant primary efficacy endpoint of reduction in weekly-average Worst-Itch Numeric Rating Scale (WI-NRS) at Week 8 -- Statistically significant secondary.
